AAAAAA

   
Results: 1-8 |
Results: 8
Influence of cellular factors and pharmacokinetics on the formation of platinum-DNA adducts in leukocytes of children receiving cisplatin therapy
Authors: Veal, GJ Dias, C Price, L Parry, A Errington, J Hale, J Pearson, ADJ Boddy, AV Newell, DR Tilby, MJ
Citation: Gj. Veal et al., Influence of cellular factors and pharmacokinetics on the formation of platinum-DNA adducts in leukocytes of children receiving cisplatin therapy, CLIN CANC R, 7(8), 2001, pp. 2205-2212
Antibody recognition of melphalan adducts characterized using immobilized DNA: Enhanced alkylation of g-rich regions in cells compared to in vitro
Authors: McCartney, H Martin, AM Middleton, PG Tilby, MJ
Citation: H. Mccartney et al., Antibody recognition of melphalan adducts characterized using immobilized DNA: Enhanced alkylation of g-rich regions in cells compared to in vitro, CHEM RES T, 14(1), 2001, pp. 71-81
Measurement of covalent drug-DNA interactions at the nucleotide level in cells at pharmacologically relevant doses
Authors: McGurk, CJ McHugh, PJ Tilby, MJ Grimaldi, KA Hartley, JA
Citation: Cj. Mcgurk et al., Measurement of covalent drug-DNA interactions at the nucleotide level in cells at pharmacologically relevant doses, METH ENZYM, 340, 2001, pp. 358-376
An investigation into the formation of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA) and 6-[2-(dimethylamino)ethylamino]-3-hydroxy-7H-indeno[2,1-c]quinolin-7-one dihydrochloride (TAS-103) stabilised DNA topoisomerase I and II cleavable complexes in human leukaemia cells
Authors: Padget, K Stewart, A Charlton, P Tilby, MJ Austin, CA
Citation: K. Padget et al., An investigation into the formation of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA) and 6-[2-(dimethylamino)ethylamino]-3-hydroxy-7H-indeno[2,1-c]quinolin-7-one dihydrochloride (TAS-103) stabilised DNA topoisomerase I and II cleavable complexes in human leukaemia cells, BIOCH PHARM, 60(6), 2000, pp. 817-821
Camptothecin-stabilised topoisomerase I-DNA complexes in leukaemia cells visualised and quantified in situ by the TARDIS assay ((t)under-barrapped in(a)under-barga(r)under-barose (D)under-barNA (i)under-barmmuno(s)under-bartaining)
Authors: Padget, K Carr, R Pearson, ADJ Tilby, MJ Austin, CA
Citation: K. Padget et al., Camptothecin-stabilised topoisomerase I-DNA complexes in leukaemia cells visualised and quantified in situ by the TARDIS assay ((t)under-barrapped in(a)under-barga(r)under-barose (D)under-barNA (i)under-barmmuno(s)under-bartaining), BIOCH PHARM, 59(6), 2000, pp. 629-638
Pharmacokinetically guided dose escalation of carboplatin in epithelial ovarian cancer: Effect on drug-plasma AUC and peripheral blood drug-DNA adduct levels
Authors: Ghazal-Aswad, S Tilby, MJ Lind, M Baily, N Sinha, DP Calvert, AH Newell, DR
Citation: S. Ghazal-aswad et al., Pharmacokinetically guided dose escalation of carboplatin in epithelial ovarian cancer: Effect on drug-plasma AUC and peripheral blood drug-DNA adduct levels, ANN ONCOL, 10(3), 1999, pp. 329-334
Murine transgenic cells lacking DNA topoisomerase II beta are resistant toacridines and mitoxantrone: Analysis of cytotoxicity and cleavable complexformation
Authors: Errington, F Willmore, E Tilby, MJ Li, L Li, G Li, W Baguley, BC Austin, CA
Citation: F. Errington et al., Murine transgenic cells lacking DNA topoisomerase II beta are resistant toacridines and mitoxantrone: Analysis of cytotoxicity and cleavable complexformation, MOLEC PHARM, 56(6), 1999, pp. 1309-1316
Measuring DNA adducts by immunoassay (ELISA)
Authors: Tilby, MJ
Citation: Mj. Tilby, Measuring DNA adducts by immunoassay (ELISA), METH MOL M, 28, 1999, pp. 121-128
Risultati: 1-8 |